Canada grants full approval to Johnson & Johnson's COVID-19 shot

Health Canada has updated its labels for the AstraZeneca and the Johnson & Johnson COVID-19 vaccines to add immune thrombocytopenia (ITP) as a potential side-effect. The autoimmune condition, which can cause easy or excessive bruising and bleeding, has been reported in very rare cases internationally after receiving the vaccines.

Johnson & Johnson said on Wednesday Canada gave full approval to its single-shot COVID-19 vaccine for people aged 18 years and older, making it the first full approval for the vaccine globally.

The vaccine was previously authorized by the country under an interim order.

Canada, which is reporting 2,563 infections on average each day and has administered at least 60,101,058 doses of COVID-19 vaccines so far, gave full approval to Moderna Inc and Pfizer Inc’s coronavirus vaccines in September.

Read more:

Canada to donate 10M J&J COVID-19 vaccine doses to poorer countries

The country authorized the use of Pfizer’s COVID-19 vaccine for children aged 5 to 11 and a booster dose for people aged 18 years and older this month.

J&J’s coronavirus vaccine has been authorized for emergency use in many countries, including the United States.

(Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta)

© 2021 Reuters

You May Also Like

Top Stories